If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
===== Alternative ===== TH2 cells play an important role in alternative macrophage activation as part of type 2 immune response against large extracellular pathogens like helminths. TH2 cells secrete IL-4 and IL-13, which activate macrophages to become M2 macrophages, also known as alternatively activated macrophages. M2 macrophages express arginase-1, an enzyme that converts arginine to ornithine and urea. Ornithine help increase smooth muscle contraction to expel the worm and also participates in tissue and wound repair. Ornithine can be further metabolized to proline, which is essential for synthesizing collagen. M2 macrophages can also decrease inflammation by producing IL-1 receptor antagonist (IL-1RA) and IL-1 receptors that do not lead to downstream inflammatory signaling (IL-1RII).
Most automotive engines are "water"-cooled to remove waste heat, though the "water" used is actually a mixture of water and antifreeze. The term engine coolant is widely used in the automotive industry, which covers its primary function of convective heat transfer for internal combustion engines. When used in an automotive context, corrosion inhibitors are added to help protect vehicles' radiators, which often contain a range of electrochemically incompatible metals (aluminum, cast iron, copper, brass, solder, etc.). Water pump seal lubricant is also added. Antifreeze was developed to overcome the shortcomings of water as a heat transfer fluid. On the other hand, if the engine coolant gets too hot, it might boil while inside the engine, causing voids (pockets of steam), leading to localized hot spots and the catastrophic failure of the engine. If plain water were to be used as an engine coolant in northern climates freezing would occur, causing significant internal engine damage. Also, plain water would increase the prevalence of galvanic corrosion. Proper engine coolant and a pressurized coolant system obviate these shortcomings of water. With proper antifreeze, a wide temperature range can be tolerated by the engine coolant, such as −34 °F (−37 °C) to +265 °F (129 °C) for 50% (by volume) propylene glycol diluted with distilled water and a 15 psi pressurized coolant system. Early engine coolant antifreeze was methanol (methyl alcohol). Ethylene glycol was developed because its higher boiling point was more compatible with heating systems.
Carey (1940), executive officer of the American Association for the Advancement of Science and publisher of Science 1975–1987 Robert Bleiberg (1943), former publisher and managing editor of Barron's Gilman Kraft (1947), former owner and publisher of Playbill Jason Epstein (1949), editorial director of Random House and co-founder of the New York Review of Books Bernard Shir-Cliff (1949), editor of Ballantine Books and Warner Books Arthur Ochs Sulzberger (1951), publisher of The New York Times Lee Guittar (1953), former publisher of the San Francisco Examiner, The Denver Post, Dallas Times Herald, and president of USA Today Richard Goodwin Capen, Jr. (1956), former publisher of the Miami Herald; U.S. ambassador to Spain 1992–1993 Peter Mayer (1956), publisher of Overlook Press and former CEO of Penguin Books Daniel Leab (1957), historian, antiquarian and publisher book catalogues, former editor of Labor History Donald Welsh (1965), founding publisher of outdoors magazine Outside Albert Scardino (1970), publisher of The Georgia Gazette and Pulitzer Prize winner in 1984 Louis Rossetto (1971), founder and publisher of Wired magazine David Rothkopf (1977), CEO and editor of Foreign Policy magazine John R. MacArthur (1978), president and publisher of Harper's magazine, grandson of billionaire John D. MacArthur, benefactor of the MacArthur Fellows Program Jake Dobkin (1998), co-founder and publisher of Gothamist franchise
SHIELD Illinois was the SHIELD Deployment Unit of the University of Illinois System charged with administering the covidSHIELD SARS-CoV-2 assay throughout the State of Illinois. SHIELD Illinois performed over 7.2 million SARS-CoV-2 assays during its initial program. This represented 12% of all SARS-CoV-2 tests in Illinois and more tests than 24 entire states.
== Side effects == Clinical studies have found that deramciclane is well-tolerated in humans at dosages ranging between 0.2–150 mg. All reported side effects were mild-moderate with the most common side effect being headache and dizziness. No severe side effects were reported in any clinical trial, and no side effects were found to be dose-dependent. Trial participants showed no significant increases in liver enzyme activity and no changes in ECGs, systolic blood pressure, diastolic blood pressure, HDL cholesterol, or LDL cholesterol levels. Another advantage to deramciclane is that it did not produce any withdrawal effects after long-term studies, like other anxiolytics do.
Sources: en.wikipedia.org
The drugs characteristics, including its pKa. Redistribution through an organism's tissues: Some drugs are distributed rapidly in some tissues until they reach equilibrium with the plasma concentration. However, other tissues with a slower rate of distribution will continue to absorb the drug from the plasma over a longer period. This will mean that the drug concentration in the first tissue will be greater than the plasma concentration and the drug will move from the tissue back into the plasma. This phenomenon will continue until the drug has reached equilibrium over the whole organism. The most sensitive tissue will therefore experience two different drug concentrations: an initial higher concentration and a later lower concentration as a consequence of tissue redistribution. Concentration differential between tissues. Exchange surface. Presence of natural barriers. These are obstacles to a drug's diffusion similar to those encountered during its absorption. The most interesting are: Capillary bed permeability, which varies between tissues. Blood-brain barrier: this is located between the blood plasma in the cerebral blood vessels and the brain's extracellular space. The presence of this barrier makes it hard for a drug to reach the brain. Placental barrier: this prevents high concentrations of a potentially toxic drug from reaching the foetus.
The FDA alerted medical practitioners that it had received nine additional reports of the same type and requested all health care professionals to report any such cases to the agency’s MedWatch program, or to their respective pharmaceutical manufacturers. The FDA subsequently received over a hundred additional reports of valvular heart disease in people taking fen-phen, fenfluramine alone, or dexfenfluramine alone. The FDA requested that the manufacturers of fenfluramine and dexfenfluramine stress the potential risk to the heart in the drugs' labeling and in package inserts. The FDA continued to receive reports in 1997 of valvular heart disease in people who had taken these drugs. This disease typically involves the aortic and mitral valves. After reports of valvular heart disease and pulmonary hypertension, primarily in women who had been undergoing treatment with fen-phen or (dex)fenfluramine, the FDA requested its withdrawal from the market in September 1997. The action was based on findings from doctors who had evaluated people taking these two drugs with echocardiograms, a procedure that can test the functioning of heart valves. The findings indicated that approximately 30 percent of people who had taken the combination for up to 24 months had abnormal echocardiograms, even though they had no symptoms. This percentage of abnormal test results was much higher than would be expected from a sample of the population who had not been exposed to either fenfluramine or dexfenfluramine.
ABPP can be analyzed using several complementary detection strategies, each suited to different experimental contexts. These methods generally visualize or enrich the enzyme-probe adduct, enabling qualitative assessment, quantitative comparison, or protein identification by mass spectrometry. One of the earliest and most widely used ABPP workflows employs direct visualization on SDS-PAGE gels. Probes with fluorescent reporter tags (e.g. rhodamine) generate distinct bands corresponding to labeled enzymes, allowing rapid assessment of activity across samples or treatment conditions. This approach is commonly used for broad enzyme families such as serine hydrolases or cysteine proteases and is compatible with high-throughput screening for inhibitors. Because the readout is based on in-gel fluorescence rather than protein abundance, gel-based ABPP readily distinguishes active from inactive enzyme species. However, a significant limitation of gel-based detection is lack of resolving ability, preventing the resolution and identification of low-abundance proteins. In recent years ABPP has been combined with tandem mass spectrometry enabling the identification of hundreds of active enzymes from a single sample. This technique, known as ABPP-MudPIT (multidimensional protein identification technology) is especially useful for profiling inhibitor selectivity as the potency of an inhibitor can be tested against hundreds of targets simultaneously. For proteome-wide analysis, ABPs incorporating affinity tags (e.g.
10 January – First Minister Humza Yousaf confirms those in Scotland convicted because of the Post Office scandal will be cleared following a similar announcement at Westminster for England and Wales, and that he will work with the UK government to bring this about. It is reported that David Page, the deputy chief officer at Police Scotland and the force's most senior member of civilian staff, has made a complaint against new Chief Constable Jo Farrell, doing so within weeks of her arrival. 11 January – First Minister Humza Yousaf confirms that the Scottish Government will "in essence replicate" the law in England and Wales banning unlicensed ownership of American XL bully dogs. Plans are announced for West Town, a £2bn 7,000 home development on land near Edinburgh Airport. 13 January – A 70-year-old woman is charged after a car ran into protesters at a pro-Palestine march in Edinburgh. 14 January – Ramsay El-Nakla, the brother-in-law of Humza Yousaf, has been charged by police in connection with drugs offences. 15 January – Robert O'Brien and Andrew Kelly are sentenced to life imprisonment with minimum terms of 22 and 18 years respectively for the 1996 murder of Caroline Glachan. James Stockan announces he will step down from the post of leader of Orkney Islands Council, as well as relinquishing his council seat, after six years in the role. 16 January – A yellow weather warning is in place for snow and ice for the whole of Scotland.
Sources: en.wikipedia.org
== Importance in metabolism == For soil bacteria, creatinase allows for organisms to process the carbon and nitrogen that come from animal wastes, degrading creatine that is made in the kidney, liver, and pancreas and excreted through urine. Animal tissues use creatine to buffer the charging of high-energy carriers during rapid ADP to ATP conversion, which creates 1-methylhydantoin. To avoid build up, animals excrete creatine and creatinine in urine. In humans, creatinase is used in enzymatic measurements of creatinine concentration for the diagnosis of renal and muscle diseases. The enzyme catalyzes the second step of a coupled creatine assay, which is used to monitor the filtration rate of the glomeruli of the kidneys.
=== May 2009 === On 18 May 2009, the SENSEX surged up 2,110.79 points to close at 14,285.21, from its previous closing of 12,174.42, for its largest single day rally. Less than a month later, on 4 June 2009, the SENSEX would cross the 15,000 mark. However, the SENSEX remained volatile during the summer of 2009. The SENSEX plunged by 869.65 points on 6 July 2009, the day of Union Budget presentation in Parliament on concerns over high fiscal deficit. This was the biggest Budget-day loss for the index. On 17 August 2009, the SENSEX lost 626.71 points. Once again, the SENSEX would recover from the volatility. On 7 September 2009, the SENSEX crossed the 16,000 mark, closing at 16,016.32 points. The index would gain 3,000 points over the next 12 months, as the SENSEX crossed the 19,000 mark on 13 September 2010, closing at 19,208.33 points.
==== Other pain ==== Paracetamol fails to relieve procedural pain in newborn babies. For perineal pain postpartum paracetamol appears to be less effective than nonsteroidal anti-inflammatory drugs (NSAIDs). The studies to support or refute the use of paracetamol for cancer pain and neuropathic pain are lacking. There is limited evidence in favor of the use of the intravenous form of paracetamol for acute pain control in the emergency department. The combination of paracetamol with caffeine is superior to paracetamol alone for the treatment of acute pain.
Highly popular Fast Forward holds influence over the other foster children, introducing them to drugs and pressuring them to give him money. Demon's mom, now pregnant, overdoses on oxyContin for the second time and dies. Demon returns for the funeral and spends Christmas with the Peggots, joining them on another trip to Knoxville. June has decided to move back to Lee County due to her colleagues in Knoxville demeaning her for being a 'redneck'. Demon begs the Peggots to adopt him, but they apologize and tell him their old age makes it impossible. A heartbroken Demon leaves Creaky Farms and is sent to stay with another neglectful foster family, the McCobbs, where he largely goes hungry and is made to feel like a financial burden. He is able to save some money by working for Mr. Ghali, a Dalit immigrant from India, who runs a garbage disposal operation (and implied meth lab) out of a gas station. Demon, now in fifth grade, remains neglected at home and is mocked at school for his unkempt appearance and bad smell. The McCobbs are forced to move due to financial issues. Demon runs away to avoid another foster placement. Neglected and hungry, Demon decides to hitchhike to Murder Valley, Tennessee, to find his paternal grandmother. He finds his grandmother Betsy Woodall, a hardy old woman who lives with her disabled brother Dick. Betsy contacts Coach Winfield, the coach of the Lee High Generals, who takes Demon in. Demon moves to Coach's mansion where he meets his daughter Agnes (nicknamed Angus after a misunderstanding) and a young man named U-Haul who assists Coach.
By exploiting this effect, conformational analysis can be used to design molecules that possess enhanced reactivity. The physical processes which give rise to bond rotation barriers are complex, and these barriers have been extensively studied through experimental and theoretical methods. A number of recent articles have investigated the predominance of the steric, electrostatic, and hyperconjugative contributions to rotational barriers in ethane, butane, and more substituted molecules.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.